Form 4: Neuronetics CEO Keith J. Sullivan Acquires Shares and Performance Restricted Stock Units

Keith J. Sullivan, President and CEO of Neuronetics, Inc., reports acquisition of common stock and performance-based restricted stock units.

Summary

• On February 24, 2025, Keith J. Sullivan, the President and CEO of Neuronetics, Inc., acquired 375,000 shares of common stock and 187,500 performance restricted stock units (PRSUs).
• The common stock was acquired at a price of $0 per share.
• The PRSUs vest in three tranches on December 31, 2025, 2026, and 2027, contingent upon performance metrics and continuous service.
• Sullivan directly owns 1,607,988 shares of Neuronetics common stock following the reported transaction.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing simply reports transactions by an insider, which is a normal part of corporate governance. The acquisition of shares and PRSUs could be seen as a positive signal, but it's not definitive.

Positives

• The acquisition of shares and PRSUs by the CEO could be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

The vesting of the PRSUs is contingent upon the company's performance and the CEO's continued service, aligning his interests with those of the shareholders.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Stock and RSU grants are a common form of executive compensation in publicly traded companies, particularly in the biotech and medical device industries.
• Companies like Medtronic, Boston Scientific, and Abbott also utilize similar equity-based compensation plans to incentivize their executives.

Stakeholder Impact

• The acquisition of shares and PRSUs by the CEO aligns his interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates